QPWM
TEVA icon

Quadrant Private Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Quadrant Private Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,056
Closed -$110K – 261
2022
Q4 		$110K Buy
+12,056
New +$105K 0.04% 237
2022
Q2 		$91K Hold
12,056
– – 0.04% 201
2022
Q1 		$113K Sell
12,056
-700
-5% -$5.84K 0.04% 202
2021
Q4 		$102K Sell
12,756
-1,600
-11% -$14.4K 0.04% 198
2021
Q3 		$140K Sell
14,356
-3,200
-18% -$30K 0.06% 187
2021
Q2 		$174K Sell
17,556
-3,200
-15% -$33.9K 0.07% 187
2021
Q1 		$240K Sell
20,756
-3,100
-13% -$35.5K 0.1% 168
2020
Q4 		$230K Buy
23,856
+1,100
+5% +$10.5K 0.1% 168
2020
Q3 		$205K Sell
22,756
-600
-3% -$6.35K 0.1% 164
2020
Q2 		$288K Buy
23,356
+4,800
+26% +$54.3K 0.17% 132
2020
Q1 		$167K Buy
+18,556
New +$190K 0.14% 139

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Quadrant Private Wealth Management's TEVA Position: Q1 2023 in Review

Quadrant Private Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 12,056 shares — an estimated $110K sold.

Quadrant Private Wealth Management first reported a position in TEVA in Q1 2020 and held it in 11 quarters. The position peaked at $288K in Q2 2020. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • Quadrant Private Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Quadrant Private Wealth Management sold 12,056 Teva Pharmaceuticals shares in Q1 2023, an estimated $110K.
  • Quadrant Private Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 11 quarters.
  • Quadrant Private Wealth Management's Teva Pharmaceuticals position peaked at $288K in Q2 2020.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Quadrant Private Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.